Interleukin-1β Inhibition Linked to Reduced Incidence of Anemia
Among those with baseline anemia, hemoglobin levels improved with canakinumab versus placebo.
Anemias
Bleeding Incidences in Patients With Sickle Cell Disease
The authors included 6423 patients with SCD in what is believed to be the first study of the incidence of bleeding events in this patient population.
ADT Use for Prostate Cancer Increases Anemia Risk
Treatment with androgen deprivation therapy alone is associated with increased risks for anemia compared with radical prostatectomy alone, a study found.
Improved Neurocognitive Function With Hydroxycarbamide in Adolescents With Sickle Cell Disease
Patients who received hydroxycarbamide therapy scored higher on several measures of neurocognition compared to patients who did not receive hydroxycarbamide.
Clinical Profiles of Patients With Diamond-Blackfan Anemia
Using data from a nationwide registry, researchers characterized the clinical profiles of patients with Diamond-Blackfan anemia.
Nonanemic Iron Deficiency Associated With Increased Risk for Mortality
Gender, alcohol consumption, and levels of C-reactive protein and fibrinogen were found to be associated with prevalence of nonanemic absolute iron deficiency.
Vitamin D Deficiency and Hospital-Related Outcomes for Patients With Sickle Cell Disease
Patients with sickle cell disease and vitamin D deficiency reported higher rates of emergency room visits and hospital admissions for pain crises.
New ASH Clinical Guidelines on Transfusion Support for Sickle Cell Disease
A panel of researchers developed evidence-based guidelines to support clinical decision making regarding transfusion support for patients with sickle cell disease.
Thromboembolism Incidence With Splenectomy for Automimmune Hemolytic Anemia
Patients with autoimmune hemolytic anemia who underwent splenectomy experienced increased cumulative incidences of thromboembolism and sepsis.
Reduced Transfusion Burden With Luspatercept in Anemia From Lower-Risk Myelodysplastic Syndromes
Transfusion independence for at least 8 weeks was observed in 38% of patients receiving luspatercept compared with 13% of patients receiving placebo.
Next post in Myelodysplastic Syndromes
